제품 수집
제품 세부정보
Source
Biotinylated Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-BLY73) is a mouse monoclonal antibody produced from a hybridoma generated by fusion of SP2/0 myeloma cells with mouse B lymphocytes.
Antibody Type
Hybridoma Monoclonal
Clone
AY73
Isotype
Mouse IgG1, Kappa
Host Species
Mouse
Immunogen
DM-1
Conjugate
Biotinylated
Specificity
This monoclonal antibody specifically recognizes both DM-1 and DM-4.
Purification
Protein A purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
Bioactivity-ELISA
Immobilized Trastuzumab-DM1 (T-DM1) at 2 μg/mL (100 μL/well) can bind Biotinylated Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified) (Cat. No. DM1-BLY73) with a linear range of 0.98-31.25 ng/mL (QC tested).
Protocol
Immobilized Human Her2 / ErbB2 (498-648) Protein, His Tag (Cat. No. HE2-H52H4) at 2 μg/mL, add increasing concentrations of Trastuzumab-DM1 (T-DM1), and then add Biotinylated Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified) (Cat. No. DM1-BLY73) at 0.5 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 1.95 ng/mL (Routiney tested).
Protocol
Immobilized ADC-DM4 at 2 μg/mL (100 μL/well) can bind Biotinylated Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified) (Cat. No. DM1-BLY73) with a linear range of 1.95-62.5 ng/mL (Routiney tested).
Protocol
Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Trastuzumab-DM1 in the 100% Human Serum and then add Biotinylated Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-BLY73) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Trastuzumab-DM1 in the 0.5% BSA and then add HRP conjugated Biotinylated Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-BLY73) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).
Protocol
사용자 리뷰 댓글 남기기
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
배경 소개
프론티어 진행
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
